Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a report released on Friday.

A number of other research firms also recently weighed in on KLRS. Raymond James Financial initiated coverage on Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating on the stock. Weiss Ratings reissued a “sell (e)” rating on shares of Kalaris Therapeutics in a research note on Saturday, September 27th. Finally, Piper Sandler set a $3.00 price target on Kalaris Therapeutics and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.00.

Kalaris Therapeutics Stock Performance

KLRS stock opened at $6.64 on Friday. The company has a fifty day moving average of $3.79. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $24.15.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Institutional Investors Weigh In On Kalaris Therapeutics

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics Inc. (NASDAQ:KLRS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,234 shares of the company’s stock, valued at approximately $65,000. XTX Topco Ltd owned approximately 0.13% of Kalaris Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.